{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:58:49Z","timestamp":1790816329564,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92741-y","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T18:55:21Z","timestamp":1742237721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Disproportionality analysis of post-marketing safety concerns associated with selumetinib in the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Fengfen","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"92741_CR1","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1002\/ajmg.a.33139(2010)","volume":"152a","author":"DG Evans","year":"2010","unstructured":"Evans, D. G. et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. Genet. A 152a, 327\u2013332. https:\/\/doi.org\/10.1002\/ajmg.a.33139(2010) (2010).","journal-title":"Am. J. Med. Genet. A"},{"key":"92741_CR2","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1177\/10600280211046298","volume":"56","author":"MK Anderson","year":"2022","unstructured":"Anderson, M. K., Johnson, M., Thornburg, L. & Halford, Z. A review of selumetinib in the treatment of neurofibromatosis type 1-related plexiform neurofibromas. Ann. Pharmacother. 56, 716\u2013726. https:\/\/doi.org\/10.1177\/10600280211046298 (2022).","journal-title":"Ann. Pharmacother."},{"key":"92741_CR3","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560. https:\/\/doi.org\/10.1056\/NEJMoa1605943 (2016).","journal-title":"N. Engl. J. Med."},{"key":"92741_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1542\/peds.105.3.608","volume":"105","author":"K DeBella","year":"2000","unstructured":"DeBella, K., Szudek, J. & Friedman, J. M. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 105, 608\u2013614. https:\/\/doi.org\/10.1542\/peds.105.3.608 (2000).","journal-title":"Pediatrics"},{"key":"92741_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/s1474-4422(14)70063-8","volume":"13","author":"AC Hirbe","year":"2014","unstructured":"Hirbe, A. C. & Gutmann, D. H. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 13, 834\u2013843. https:\/\/doi.org\/10.1016\/s1474-4422(14)70063-8 (2014).","journal-title":"Lancet Neurol."},{"key":"92741_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41571-020-0361-7","volume":"17","author":"D Killock","year":"2020","unstructured":"Killock, D. Selumetinib benefits children with inoperable plexiform neurofibromas. Nat. Rev. Clin. Oncol. 17, 273. https:\/\/doi.org\/10.1038\/s41571-020-0361-7 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"92741_CR7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","volume":"160","author":"CE Prada","year":"2012","unstructured":"Prada, C. E. et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J. Pediatr. 160, 461\u2013467. https:\/\/doi.org\/10.1016\/j.jpeds.2011.08.051 (2012).","journal-title":"J. Pediatr."},{"key":"92741_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3171\/2012.9.Jns101610","volume":"118","author":"GP Dunn","year":"2013","unstructured":"Dunn, G. P. et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J. Neurosurg. 118, 142\u2013148. https:\/\/doi.org\/10.3171\/2012.9.Jns101610 (2013).","journal-title":"J. Neurosurg."},{"key":"92741_CR9","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1158\/1078-0432.Ccr-20-5032","volume":"27","author":"D Casey","year":"2021","unstructured":"Casey, D. et al. FDA approval summary: Selumetinib for plexiform neurofibroma. Clin. Cancer Res. 27, 4142\u20134146. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-5032 (2021).","journal-title":"Clin. Cancer Res."},{"key":"92741_CR10","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/cmr.0000000000000618","volume":"29","author":"N Mourad","year":"2019","unstructured":"Mourad, N. et al. Severe gastrointestinal toxicity of MEK inhibitors. Melanoma Res. 29, 556\u2013559. https:\/\/doi.org\/10.1097\/cmr.0000000000000618 (2019).","journal-title":"Melanoma Res."},{"key":"92741_CR11","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1634\/theoncologist.2019-0297","volume":"25","author":"A Bardia","year":"2020","unstructured":"Bardia, A. et al. Phase Ib study of combination therapy with MEK inhibitor binimetinib and phosphatidylinositol 3-kinase inhibitor buparlisib in patients with advanced solid tumors with RAS\/RAF alterations. Oncologist 25, e160\u2013e169. https:\/\/doi.org\/10.1634\/theoncologist.2019-0297 (2020).","journal-title":"Oncologist"},{"key":"92741_CR12","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1212\/wnl.0000000000013296","volume":"98","author":"J Hwang","year":"2022","unstructured":"Hwang, J., Yoon, H. M., Lee, B. H., Kim, P. H. & Kim, K. W. Efficacy and safety of selumetinib in pediatric patients with neurofibromatosis type 1: A Systematic review and meta-analysis. Neurology 98, e938\u2013e946. https:\/\/doi.org\/10.1212\/wnl.0000000000013296 (2022).","journal-title":"Neurology"},{"key":"92741_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ygyno.2021.05.012","volume":"162","author":"Z Ma","year":"2021","unstructured":"Ma, Z. et al. Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. Gynecol. Oncol. 162, 496\u2013505. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.012 (2021).","journal-title":"Gynecol. Oncol."},{"key":"92741_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.894685","volume":"13","author":"Z Feng","year":"2022","unstructured":"Feng, Z. et al. Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS. Front. Pharmacol. 13, 894685. https:\/\/doi.org\/10.3389\/fphar.2022.894685 (2022).","journal-title":"Front. Pharmacol."},{"key":"92741_CR15","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 47, 585\u2013599. https:\/\/doi.org\/10.1007\/s40264-024-01423-7 (2024).","journal-title":"Drug Saf."},{"key":"92741_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","volume":"19","author":"B Zhao","year":"2023","unstructured":"Zhao, B., Zhang, X., Chen, M. & Wang, Y. A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database. Expert Opin. Drug Metab. Toxicol. 19, 381\u2013387. https:\/\/doi.org\/10.1080\/17425255.2023.2235267 (2023).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"92741_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7150\/ijms.7967","volume":"11","author":"T Sakaeda","year":"2014","unstructured":"Sakaeda, T., Kadoyama, K., Minami, K. & Okuno, Y. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. Int. J. Med. Sci. 11, 461\u2013465. https:\/\/doi.org\/10.7150\/ijms.7967 (2014).","journal-title":"Int. J. Med. Sci."},{"key":"92741_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek, E. P. et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol. Drug Saf. 11, 3\u201310. https:\/\/doi.org\/10.1002\/pds.668 (2002).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"92741_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol. Drug Saf. 18, 427\u2013436. https:\/\/doi.org\/10.1002\/pds.1742 (2009).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"92741_CR20","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","volume":"25","author":"AM Gross","year":"2023","unstructured":"Gross, A. M. et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 25, 1883\u20131894. https:\/\/doi.org\/10.1093\/neuonc\/noad086 (2023).","journal-title":"Neuro Oncol."},{"key":"92741_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","volume":"17","author":"M Banks","year":"2017","unstructured":"Banks, M., Crowell, K., Proctor, A. & Jensen, B. C. Cardiovascular effects of the MEK inhibitor, trametinib: A case report, literature review, and consideration of mechanism. Cardiovasc. Toxicol. 17, 487\u2013493. https:\/\/doi.org\/10.1007\/s12012-017-9425-z (2017).","journal-title":"Cardiovasc. Toxicol."},{"key":"92741_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00395-007-0658-z","volume":"102","author":"P Fischer","year":"2007","unstructured":"Fischer, P. & Hilfiker-Kleiner, D. Survival pathways in hypertrophy and heart failure: the gp130-STAT3 axis. Basic Res. Cardiol. 102, 279\u2013297. https:\/\/doi.org\/10.1007\/s00395-007-0658-z (2007).","journal-title":"Basic Res. Cardiol."},{"key":"92741_CR23","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","volume":"90","author":"BA Rose","year":"2010","unstructured":"Rose, B. A., Force, T. & Wang, Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90, 1507\u20131546. https:\/\/doi.org\/10.1152\/physrev.00054.2009 (2010).","journal-title":"Physiol. Rev."},{"key":"92741_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1172\/jci119709","volume":"100","author":"R Aikawa","year":"1997","unstructured":"Aikawa, R. et al. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J. Clin. Invest. 100, 1813\u20131821. https:\/\/doi.org\/10.1172\/jci119709 (1997).","journal-title":"J. Clin. Invest."},{"key":"92741_CR25","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1161\/01.res.0000038488.38975.1a","volume":"91","author":"OF Bueno","year":"2002","unstructured":"Bueno, O. F. & Molkentin, J. D. Involvement of extracellular signal-regulated kinases 1\/2 in cardiac hypertrophy and cell death. Circ. Res. 91, 776\u2013781. https:\/\/doi.org\/10.1161\/01.res.0000038488.38975.1a (2002).","journal-title":"Circ. Res."},{"key":"92741_CR26","doi-asserted-by":"publisher","first-page":"H1925","DOI":"10.1152\/ajpheart.01054.2004","volume":"288","author":"H Lou","year":"2005","unstructured":"Lou, H., Danelisen, I. & Singal, P. K. Involvement of mitogen-activated protein kinases in adriamycin-induced cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 288, H1925-1930. https:\/\/doi.org\/10.1152\/ajpheart.01054.2004 (2005).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"92741_CR27","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1200\/jco.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139\u20132146. https:\/\/doi.org\/10.1200\/jco.2007.14.4956 (2008).","journal-title":"J. Clin. Oncol."},{"key":"92741_CR28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s1470-2045(12)70572-7","volume":"14","author":"J Farley","year":"2013","unstructured":"Farley, J. et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 14, 134\u2013140. https:\/\/doi.org\/10.1016\/s1470-2045(12)70572-7 (2013).","journal-title":"Lancet Oncol."},{"key":"92741_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ygyno.2015.04.005","volume":"138","author":"RL Coleman","year":"2015","unstructured":"Coleman, R. L. et al. A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1\/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: an NRG oncology\/gynecologic oncology group study. Gynecol. Oncol. 138, 30\u201335. https:\/\/doi.org\/10.1016\/j.ygyno.2015.04.005 (2015).","journal-title":"Gynecol. Oncol."},{"key":"92741_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ctrv.2013.01.003","volume":"39","author":"R van der Noll","year":"2013","unstructured":"van der Noll, R., Leijen, S., Neuteboom, G. H., Beijnen, J. H. & Schellens, J. H. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat. Rev. 39, 664\u2013672. https:\/\/doi.org\/10.1016\/j.ctrv.2013.01.003 (2013).","journal-title":"Cancer Treat. Rev."},{"key":"92741_CR31","doi-asserted-by":"publisher","first-page":"e3457","DOI":"10.1097\/md.0000000000003457","volume":"95","author":"EHC van Dijk","year":"2016","unstructured":"van Dijk, E. H. C. et al. Loss of MAPK pathway activation in post-mitotic retinal cells as mechanism in MEK inhibition-related retinopathy in cancer patients. Medicine (Baltimore) 95, e3457. https:\/\/doi.org\/10.1097\/md.0000000000003457 (2016).","journal-title":"Medicine (Baltimore)"},{"key":"92741_CR32","doi-asserted-by":"publisher","first-page":"e96365","DOI":"10.1371\/journal.pone.0096365","volume":"9","author":"X Chen","year":"2014","unstructured":"Chen, X. et al. The complex interplay between ERK1\/2, TGF\u03b2\/Smad, and Jagged\/Notch signaling pathways in the regulation of epithelial-mesenchymal transition in retinal pigment epithelium cells. PLoS One 9, e96365. https:\/\/doi.org\/10.1371\/journal.pone.0096365 (2014).","journal-title":"PLoS One"},{"key":"92741_CR33","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/ajd.14079","volume":"64","author":"AG Palmeiro","year":"2023","unstructured":"Palmeiro, A. G. et al. MEK inhibitor-induced paronychia in a paediatric population: A tertiary centre experience. Australas J. Dermatol. 64, e245\u2013e251. https:\/\/doi.org\/10.1111\/ajd.14079 (2023).","journal-title":"Australas J. Dermatol."},{"key":"92741_CR34","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.jaad.2020.07.044","volume":"84","author":"CL Boull","year":"2021","unstructured":"Boull, C. L. et al. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study. J. Am. Acad. Dermatol. 84, 1554\u20131561. https:\/\/doi.org\/10.1016\/j.jaad.2020.07.044 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"92741_CR35","unstructured":"Zhou, C., Davis, D., Haskell, H. & Levin, J. Journal of the American Academy of Dermatology. AB92-AB92 (mosby-elsevier 360 park avenue South, New York, NY 10010\u20131710 USA)."},{"key":"92741_CR36","unstructured":"U.S. Food and Drug Administration. Koselugo (selumetinib) prescribing information. https:\/\/www.accessdata.fda.gov. (2024)."},{"key":"92741_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/cmr.0000000000000186","volume":"25","author":"YJ Jansen","year":"2015","unstructured":"Jansen, Y. J. et al. Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Res. 25, 550\u2013554. https:\/\/doi.org\/10.1097\/cmr.0000000000000186 (2015).","journal-title":"Melanoma Res."},{"key":"92741_CR38","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s40620-023-01736-3","volume":"36","author":"F Garo","year":"2023","unstructured":"Garo, F., Reboul, P., Gerbal, M. & Moranne, O. Granulomatous interstitial nephritis following BRAF\/MEK inhibitor treatment for metastatic melanoma. J. Nephrol. 36, 2649\u20132650. https:\/\/doi.org\/10.1007\/s40620-023-01736-3 (2023).","journal-title":"J. Nephrol."},{"key":"92741_CR39","doi-asserted-by":"publisher","first-page":"e1520","DOI":"10.1002\/cnr2.1520","volume":"5","author":"A Krelle","year":"2022","unstructured":"Krelle, A. et al. Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib\u2014A case report. Cancer Rep. (Hoboken) 5, e1520. https:\/\/doi.org\/10.1002\/cnr2.1520 (2022).","journal-title":"Cancer Rep. (Hoboken)"},{"key":"92741_CR40","doi-asserted-by":"publisher","first-page":"e28485","DOI":"10.1097\/md.0000000000028485","volume":"101","author":"E Jo","year":"2022","unstructured":"Jo, E. & Rhee, H. Dabrafenib- and trametinib-associated glomerular toxicity: A case report. Medicine (Baltimore) 101, e28485. https:\/\/doi.org\/10.1097\/md.0000000000028485 (2022).","journal-title":"Medicine (Baltimore)"},{"key":"92741_CR41","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/bjd.12555","volume":"169","author":"E Regnier-Rosencher","year":"2013","unstructured":"Regnier-Rosencher, E. et al. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas. Br. J. Dermatol. 169, 934\u2013938. https:\/\/doi.org\/10.1111\/bjd.12555 (2013).","journal-title":"Br. J. Dermatol."},{"key":"92741_CR42","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2215\/cjn.06100616","volume":"12","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo, R. et al. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin. J. Am. Soc. Nephrol. 12, 176\u2013189. https:\/\/doi.org\/10.2215\/cjn.06100616 (2017).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"92741_CR43","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo, P. M. et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front. Drug Saf. Regul. 3, 1323057 (2024).","journal-title":"Front. Drug Saf. Regul."},{"key":"92741_CR44","doi-asserted-by":"publisher","first-page":"1241524","DOI":"10.3389\/fphar.2023.1241524","volume":"14","author":"JM Schilder","year":"2023","unstructured":"Schilder, J. M., Golembesky, A., Boyle, T. A. C., Ye, G. L. & Kuplast, J. Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS. Front. Pharmacol. 14, 1241524. https:\/\/doi.org\/10.3389\/fphar.2023.1241524 (2023).","journal-title":"Front. Pharmacol."},{"key":"92741_CR45","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1002\/sim.8745","volume":"39","author":"SJ Heo","year":"2020","unstructured":"Heo, S. J. & Jung, I. Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. Stat. Med. 39, 4636\u20134650. https:\/\/doi.org\/10.1002\/sim.8745 (2020).","journal-title":"Stat. Med."},{"key":"92741_CR46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/hon.2743","volume":"38","author":"X Ye","year":"2020","unstructured":"Ye, X. et al. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019. Hematol. Oncol. 38, 565\u2013575. https:\/\/doi.org\/10.1002\/hon.2743 (2020).","journal-title":"Hematol. Oncol."},{"key":"92741_CR47","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048 (2013).","journal-title":"Int. J. Med. Sci."},{"key":"92741_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","volume":"20","author":"EG Brown","year":"1999","unstructured":"Brown, E. G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109\u2013117. https:\/\/doi.org\/10.2165\/00002018-199920020-00002 (1999).","journal-title":"Drug Saf."},{"key":"92741_CR49","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","volume":"82","author":"JS Almenoff","year":"2007","unstructured":"Almenoff, J. S. et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin. Pharmacol. Ther. 82, 157\u2013166. https:\/\/doi.org\/10.1038\/sj.clpt.6100258 (2007).","journal-title":"Clin. Pharmacol. Ther."},{"key":"92741_CR50","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"92741_CR51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"92741_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman, A., Machado, S. G. & O\u2019Neill, R. T. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 25, 381\u2013392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001 (2002).","journal-title":"Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92741-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92741-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T18:55:23Z","timestamp":1742237723000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92741-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92741"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92741-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9218"}}